Business Context and Reporting Period
Company: Xeris Biopharma Holdings, Inc. (XERS)
Filing Type: Form 8-K (Current Report)
Date of Report: January 10, 2025
Reporting Period: Fourth quarter and full year ended December 31, 2024
The Company issued a press release on January 10, 2025, announcing preliminary financial results for the fourth quarter and full year 2024. This 8-K serves as a notification of those results, with the detailed data contained in the attached press release (Exhibit 99.1).
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the preliminary results are disclosed in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the issuance of preliminary results for the period ended December 31, 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing the preliminary results but does not include the text of that commentary.
Legal Disclaimer: The information furnished under Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for Q4 and full-year 2024.
- Verify the Company's cash runway and burn rate based on the preliminary results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm if the preliminary results include any restatements or adjustments to prior periods.